Anti-tumor Specific Immune Response in Head and Neck Cancers

Study Overview
=================
Brief Summary
-----------------
The purpose is the description of anti-tumor immune responses in general and according to clinical stage and disease free survival (DFS: survival without recurrence (local or distant)) in patients with Head & Neck Squamous Cell Carcinoma Secondary purposes are: Study of relationship between anti-tumor immune response and qualitative (yes/no) and quantitative (number) presence of circulating tumor cells (CTCs); Study of relationship between qualitative (yes/no) and quantitative (number) presence of CTCs and clinical stage as well as DFS Study of relationship between anti-tumor immune response and clinical stage as well as DFS.

Official Title
-----------------
Anti-tumor Specific Immune Response in Head and Neck Cancers

Conditions
-----------------
Head and Neck Squamous Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with Head & Neck Squamous Cell Carcinoma after extension assessment, regardless of clinical stage (TNM UICC stage I-IV), before any medical or surgical treatment specifically directed against cancer (radiotherapy, surgery, chemotherapy or targeted therapy) Consent to participate to the study, non-opposition Affiliation to social security Exclusion Criteria: History of neoplasia, synchronous cancer, auto-immune disease, organ transplantation, chemotherapy HIV infection Corticotherapy during 15 days before blood sampling

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| squamous cell carcinoma<br>Patients affected by Head & Neck Squamous Cell Carcinoma. Blood sample at diagnosis, before any antitumor treatment | Other: Blood sample<br>* Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or absence of spontaneous responses against tumor-associated antigens (TAA) according to tumor stage |  | day 0 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional signature of T cell responses (polyfunctionality index of lymphocytes) according to tumor stage | Effector functions and phenotypes of T cells | day 0 | 
| Number of CTCs according to tumor stage |  | day 0 | 
| Polyfunctionality index of lymphocytes according to number of CTCs |  | day 0 | 
| Disease free survival (survival without local or distant recurrence) according to Presence pr absence of CTCs at diagnosis |  | 2 years after diagnosis | 
| Disease free survival (survival without local or distant recurrence) according to Presence or absence of spontaneous responses against TAA |  | 2 years after diagnosis |